A detailed history of Commodore Capital LP transactions in Merus N.V. stock. As of the latest transaction made, Commodore Capital LP holds 3,200,000 shares of MRUS stock, worth $174 Million. This represents 16.98% of its overall portfolio holdings.

Number of Shares
3,200,000
Previous 4,360,000 26.61%
Holding current value
$174 Million
Previous $196 Million 3.56%
% of portfolio
16.98%
Previous 16.96%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$39.81 - $60.2 $46.2 Million - $69.8 Million
-1,160,000 Reduced 26.61%
3,200,000 $189 Million
Q1 2024

May 15, 2024

SELL
$28.03 - $51.82 $10.9 Million - $20.1 Million
-387,373 Reduced 8.16%
4,360,000 $196 Million
Q4 2023

Feb 14, 2024

BUY
$20.06 - $28.66 $6.41 Million - $9.15 Million
319,301 Added 7.21%
4,747,373 $131 Million
Q3 2023

Nov 14, 2023

BUY
$20.13 - $27.29 $8.62 Million - $11.7 Million
428,072 Added 10.7%
4,428,072 $104 Million
Q2 2023

Aug 14, 2023

BUY
$18.33 - $27.18 $19.2 Million - $28.5 Million
1,050,000 Added 35.59%
4,000,000 $105 Million
Q1 2023

May 15, 2023

BUY
$14.25 - $20.5 $3.1 Million - $4.46 Million
217,433 Added 7.96%
2,950,000 $54.3 Million
Q4 2022

Feb 14, 2023

BUY
$12.8 - $23.66 $1.5 Million - $2.76 Million
116,805 Added 4.47%
2,732,567 $42.3 Million
Q2 2022

Aug 15, 2022

BUY
$13.98 - $29.25 $11.2 Million - $23.4 Million
799,341 Added 44.01%
2,615,762 $59.2 Million
Q1 2022

May 16, 2022

BUY
$23.58 - $30.91 $7.49 Million - $9.81 Million
317,531 Added 21.18%
1,816,421 $48 Million
Q4 2021

Feb 14, 2022

BUY
$20.0 - $32.29 $15.6 Million - $25.2 Million
780,754 Added 108.72%
1,498,890 $47.7 Million
Q3 2021

Nov 15, 2021

BUY
$16.48 - $27.23 $11.8 Million - $19.6 Million
718,136 New
718,136 $15.8 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.5B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Commodore Capital LP Portfolio

Follow Commodore Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Commodore Capital LP with notifications on news.